ADIAL PHARMACEUTICALS, INC. current report, 10 February 2022

Vollständiges Dokument

Business Context and Reporting Period

Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2022
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement.

Key Financial Metrics and Transaction Details

  • Aggregate Purchase Price: Approximately $10 million.
  • Estimated Net Proceeds: Approximately $9.1 million after deducting placement agent fees and transaction expenses.
  • Use of Proceeds: Working capital purposes.
  • Securities Issued:
    • 2,322,250 shares of Common Stock.
    • Pre-Funded Warrants to purchase up to 1,865,000 shares (exercise price $0.001).
    • Warrants to purchase up to 3,977,888 shares (exercise price $2.52; term 5.5 years).
  • Placement Agent Fee: 7% of the aggregate purchase price plus expenses not to exceed $50,000.

Material Changes and Transaction Structure

The Company entered into a Securities Purchase Agreement with an accredited institutional investor. The transaction consists of two components:

  1. Registered Offering: Issuance of Common Stock and Pre-Funded Warrants under an effective Form S-3 shelf registration statement.
  2. Private Placement: Issuance of Warrants pursuant to Section 4(a)(2) and/or Regulation D exemptions.

The Pre-Funded Warrants are immediately exercisable and were issued to ensure the investor does not exceed beneficial ownership limitations. The Warrants are exercisable on a cashless basis if no effective registration statement is filed within six months of issuance.

Outlook, Risks, and Management Commentary

  • Closing Date: Expected on or about February 15, 2022, subject to customary closing conditions.
  • Registration Obligations: The Company agreed to file a registration statement for the resale of Warrant Shares within 90 days and use commercially reasonable efforts to obtain effectiveness within 181 days.
  • Beneficial Ownership Limitations: Holders may not exercise warrants if it results in beneficial ownership exceeding 4.99% (or 9.99% with 61 days' prior notice).
  • Financial Data: This filing does not provide revenue, profit, cash flow, margin, or debt metrics. It focuses solely on the capital raise transaction.

Investor Verification Checklist

  • Verify the actual closing date and final net proceeds received.
  • Confirm the filing and effectiveness of the registration statement for the resale of Warrant Shares within the 90-day and 181-day windows.
  • Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific redemption rights or anti-dilution provisions.
  • Monitor the Company's cash position to assess the impact of the $9.1 million net proceeds on working capital runway.